Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098241 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
A Phase 3 study of Kidney Transplantation, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT00098241 is a Phase 3 study of Kidney Transplantation that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 45 participants, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00098241, a Phase 3 study of Kidney Transplantation, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
Conditions Studied
Interventions
- DRUG Certican
Study Locations (2)
Ohio
- Columbus Children's Hospital - Columbus
Other
- Dienst Pediatrie UZ Gasthuisberg, Herestraat 49 - Leuven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2000-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098241
The ClinicalTrials.gov registry entry for NCT00098241 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (83% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Certican is the first listed.
NCT00098241 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT00098241 about?
NCT00098241 is a clinical study titled "Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients". The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
What is the current status of trial NCT00098241?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2000-06. Estimated completion is 2007-03.
What conditions does trial NCT00098241 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT00098241?
The interventions under investigation include: Certican (DRUG).
Who is sponsoring clinical trial NCT00098241?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00098241 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
COMPLETED · Phase 3
-
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
COMPLETED · Phase 3
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Prehabilitation for Kidney Transplant Candidates
RECRUITING · NA
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.